e-learning
resources
Virtual 2020
Pre-Congress Content
Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Experimental modeling of lung involvement due to systemic sclerosis.
B. Doskaliuk (Ivano-Frankivsk, Ukraine), L. Zaiats (Ivano-Frankivsk, Ukraine), R. Yatsyshyn (Ivano-Frankivsk, Ukraine)
Source:
Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Session:
Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Session type:
E-poster session
Number:
749
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Doskaliuk (Ivano-Frankivsk, Ukraine), L. Zaiats (Ivano-Frankivsk, Ukraine), R. Yatsyshyn (Ivano-Frankivsk, Ukraine). Experimental modeling of lung involvement due to systemic sclerosis.. 749
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Longitudinal functional evaluation of interstitial lung disease in systemic sclerosis
Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
The natural course of systemic sclerosis patients with interstitial lung involvement
Source: Eur Respir J 2005; 26: Suppl. 49, 336s
Year: 2005
Clinical and laboratory features of systemic sclerosis with pulmonary involvement
Source: Eur Respir J 2001; 18: Suppl. 33, 512s
Year: 2001
Significance of pulmonary involvement in systemic sclerosis (SSc)– data from the German SSc-network
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Pulmonary involvement in systemic sclerosis
Source: Eur Respir Monogr 2019; 86: 90-105
Year: 2019
The genetics of systemic sclerosis
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008
Pulmonary functions in systemic sclerosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
Clinical characteristics of interstitial lung fibrosis in progressive systemic sclerosis
Source: Eur Respir J 2006; 28: Suppl. 50, 95s
Year: 2006
Applying machine learning and pulmonary function data to detect interstitial lung disease in systemic sclerosis.
Source: International Congress 2017 – Best abstracts in lung function
Year: 2017
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017
Year: 2018
Anti-a-enolase antibodies in systemic sclerosis identify a subset of patients with diffuse cutaneous sclerosis and interstitial lung disease
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Clinical feature of systemic sclerosis associated with pulmonary hypertension: results of one center study
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement
Source: Eur Respir J 2005; 26: Suppl. 49, 543s
Year: 2005
Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Pulmonary function in progressive systemic sclerosis
Source: Eur Respir J 2002; 20: Suppl. 38, 62s
Year: 2002
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease
Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Year: 2019
Interstitial lung involvement in systemic sclerosis. Correlation of HRCT and lung function tests
Source: Eur Respir J 2004; 24: Suppl. 48, 487s
Year: 2004
Survival and prognostic factors in progressive systemic sclerosis with lung involvement
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
Interstitial lung disease in systemic sclerosis: where do we stand?
Source: Eur Respir Rev 2015; 24: 411-419
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept